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Abstract
We explore mechanisms that enable cancer cells to tolerate PI3K
or Akt inhibitors. Prolonged treatment of breast cancer cells with
PI3K or Akt inhibitors leads to increased expression and activation
of a kinase termed SGK3 that is related to Akt. Under these condi-
tions, SGK3 is controlled by hVps34 that generates PtdIns(3)P,
which binds to the PX domain of SGK3 promoting phosphorylation
and activation by its upstream PDK1 activator. Furthermore, under
conditions of prolonged PI3K/Akt pathway inhibition, SGK3 substi-
tutes for Akt by phosphorylating TSC2 to activate mTORC1. We
characterise 14h, a compound that inhibits both SGK3 activity and
activation in vivo, and show that a combination of Akt and SGK
inhibitors induced marked regression of BT-474 breast cancer cell-
derived tumours in a xenograft model. Finally, we present the
kinome-wide analysis of mRNA expression dynamics induced by
PI3K/Akt inhibition. Our findings highlight the importance of the
hVps34-SGK3 pathway and suggest it represents a mechanism to
counteract inhibition of PI3K/Akt signalling. The data support the
potential of targeting both Akt and SGK as a cancer therapeutic.
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Introduction
The majority of human tumours harbour mutations promoting inap-
propriate activation of the Akt kinase, and therefore, inhibitors of
Akt and its upstream activators including Class I PI3K are being
evaluated in many cancer clinical trials (Liu et al, 2009;
Vanhaesebroeck et al, 2012; Bauer et al, 2015). Despite the benefit
observed with these molecules, drug resistance can emerge as a
result of adaptive mechanisms limiting the use of these therapies
(Rodon et al, 2013). Therefore, understanding and reverting mecha-
nisms of resistance to PI3K/Akt inhibitors is expected to improve
the success of the treatment.
The Class I PI3K family (p110a, p110b, p110c and p110d) is
activated in response to extracellular stimuli and phosphorylates the
30-hydroxyl group of the inositol moiety of membrane bound phos-
phatidylinositol 4,5-bisphosphate (PtdIns (4,5)P2) to generate PtdIns
(3,4,5)P3 (Vanhaesebroeck et al, 2001; Cantley, 2002). PtdIns(3,4,5)
P3 and its immediate breakdown product PtdIns(3,4)P2 recruit Akt
and its upstream regulator phosphoinositide-dependent kinase 1
(PDK1) to the plasma membrane via their PtdIns(3,4,5)P3/PtdIns
(3,4)P2-binding PH domains (Mora et al, 2004). This induces a
conformational change in Akt enabling PDK1 to phosphorylate its
T-loop Thr308 residue (Alessi et al, 1997a,b; Stokoe et al, 1997;
Stephens et al, 1998). Akt is fully activated following phosphoryla-
tion by mTORC2 (mammalian target of rapamycin complex-2) at the
hydrophobic motif Ser473 residue that lies within the C-terminal
non-catalytic region (Sarbassov et al, 2005). Ser473 phosphorylation
also promotes interaction of Akt with PDK1 enhancing phosphoryla-
tion of Thr308 (Najafov et al, 2012). A recent study has suggested
that PtdIns(3,4,5)P3 stimulates Ser473 phosphorylation by binding
to the PH domain of the mTORC2 complex Sin1 subunit (Liu et al,
2015).
Although the focus has been on the role that Akt isoforms play in
mediating proliferation responses that are controlled by Class I
PI3Ks, increasing evidence is accumulating that isoforms of serum
and glucocorticoid regulated kinases (SGK) which share ~50% iden-
tity within their catalytic domains to Akt, also control proliferation
and survival responses in cancer cells (Vasudevan et al, 2009;
Bruhn et al, 2010, 2013; Pearce et al, 2010; Bago et al, 2014; Gasser
et al, 2014). Although SGK1 and SGK2 isoforms lack a PH domain,
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they are still activated by Class I PI3Ks (Kobayashi & Cohen, 1999;
Kobayashi et al, 1999) through their ability to induce hydrophobic
motif phosphorylation via mTORC2, which in turn triggers phospho-
rylation of the T-loop residue by PDK1 (Biondi et al, 2001; Collins
et al, 2003, 2005). SGK and Akt kinases possess similar substrate
specificities with both enzymes preferring to phosphorylate Ser/Thr
residues lying within Arg-Xaa-Arg-Xaa-Xaa-Ser/Thr (where Xaa is
any amino acid) motifs (Alessi et al, 1996; Murray et al, 2005).
Consistent with this, several Akt substrates including FOXO tran-
scription factors (Brunet et al, 2001), GSK3 (Kobayashi & Cohen,
1999; Dai et al, 2002) and NDRG1 (Sommer et al, 2013) are simi-
larly phosphorylated by SGK1. It is therefore likely that in tumours
displaying activated PI3K signalling, both Akt1/2 and SGK1/SGK2
would be elevated and stimulate proliferation by phosphorylating
an overlapping subset of substrates. The sensitivity of a group of
breast cancer cell lines possessing mutations that activate the PI3K
pathway to Akt inhibitors has been correlated with the expression
of SGK1 in cell lines including ZR-75-1, CAMA-1 and T47D (utilised
in this study). Interestingly, these lines all contain low endogenous
SGK1 levels and are intrinsically more sensitive to Akt inhibitors
than cells that express higher levels of SGK1 (Sommer et al, 2013).
In contrast to other SGK isoforms, SGK3 possesses an N-terminal
PtdIns(3)P-binding PX domain (Virbasius et al, 2001; Bago et al,
2014) and is the only known kinase to possess a PtdIns(3)P interac-
tion domain (Pearce et al, 2010). SGK3 associates with endosome
membranes, where the Class III PI3K family member termed hVps34
phosphorylates PtdIns to generate a large fraction of the cellular
pool of PtdIns(3)P (Gillooly et al, 2000; Backer, 2008; Bago et al,
2014). Mutations within the SGK3 PX domain that ablate PtdIns(3)P
binding or treatment of cells with a hVps34 inhibitor to reduce
PtdIns(3)P levels blocked SGK3 endosomal localisation and also
suppressed SGK3 activity, by lowering phosphorylation of T-loop
and hydrophobic motifs (Bago et al, 2014).
In the present study, we demonstrate that prolonged treatment of
several breast cancer cell lines (ZR-75-1, CAMA-1, T47D and BT-
474c) harbouring mutations that activate the Akt signalling pathway
with inhibitors of Class I PI3K or Akt leads to marked upregulation
of SGK3 mRNA and subsequent activation of the SGK3 protein
kinase. Employing structurally diverse-specific hVps34 inhibitors
(VPS34-IN1 and SAR405), we establish that SGK3 activation induced
by prolonged treatment with Class I PI3K or Akt inhibitors is
controlled by hVps34. Mechanistic studies reveal that PtdIns(3)P
binding to the PX domain of SGK3 promotes phosphorylation and
activation by its upstream PDK1 activator. Moreover, we show that
following prolonged inhibition of the PI3K/Akt pathway, SGK3
could substitute for Akt and promote activation of mTORC1 and
hence S6K1 by phosphorylating TSC2 at the same sites as Akt. We
discover that a previously reported SGK1 inhibitor termed 14h
(Halland et al, 2015) also potently inhibits SGK3 (IC50 of 4 nM) with
2.5-fold higher potency than SGK1 and in addition blocks SGK3 acti-
vation by PDK1 and mTORC2 in cells. Moreover, we show that a
combination of Akt (MK-2206) and SGK (14h) inhibitors induce
marked regression of tumour volume in a nude mouse xenograft
model derived from BT-474 breast cancer cells. Finally, we present
a kinome-wide analysis of mRNA expression dynamics induced in
response to PI3K/Akt pathway inhibition. Our findings highlight the
importance of the hVps34-SGK3 pathway, which is likely to repre-
sent a major mechanism that can be used by cells to counteract inhi-
bition of the PI3K/Akt signalling network. Our results clearly
emphasise the therapeutic potential of targeting both the Akt and
SGK kinases for the treatment of cancer.
Results
Prolonged treatment with Akt and Class I PI3K inhibitors leads to
upregulation of SGK3
Treatment of breast cancer cell lines ZR-75-1 and CAMA-1 that have
low levels of SGK1 (Sommer et al, 2013) with structurally diverse
Akt inhibitors (MK-2206 (Hirai et al, 2010) and AZD5363 (Davies
et al, 2012)) for 1 h inhibited phosphorylation of PRAS40 (Thr246,
Akt-specific substrate) as well as NDRG1 (Thr346, Akt and SGK
substrate) (Fig 1A). MK-2206 is an allosteric inhibitor that
suppresses Thr308 and Ser473 phosphorylation (Hirai et al, 2010),
whereas AZD5363 is a catalytic inhibitor that although ablating Akt
activity in cells leads to increased phosphorylation of Thr308 and
Ser473 by modulating feedback loops (Davies et al, 2012). Strikingly
however, prolonged Akt inhibitor treatment over 1–10 days led to a
time-dependent recovery of NDRG1 phosphorylation, under condi-
tions where the Akt substrate PRAS40 remained dephosphorylated
(Fig 1A). Immunoblotting revealed that prolonged Akt inhibitor
treatment enhanced expression of SGK3 protein over this period
under conditions where SGK1 remained undetectable (Fig 1A).
Quantitative mRNA analysis by RT–PCR revealed that Akt inhibitors
induced 3- to 6-fold increase in SGK3 mRNA levels after 2–10 days,
whereas SGK1 or SGK2 mRNA levels were unaltered (Fig 1B). Inter-
estingly, knockdown of SGK3 protein expression employing 3
distinct shRNA probes blocked prolonged Akt inhibitor treatment
from enhancing NDRG1 phosphorylation in both ZR-75-1 and
CAMA-1 cells (Fig 1C).
Similarly, treatment of ZR-75-1, CAMA-1 and T47D cultured in
serum with structurally diverse Class I PI3K inhibitors GDC0941
(Folkes et al, 2008) and BKM120 (Bendell et al, 2012) for 1 h also
markedly suppressed NDRG1 and PRAS40 phosphorylation
(Fig 2A). Analogous to what was observed with prolonged Akt
Figure 1. Prolonged treatment with Akt inhibitors leads to upregulation of SGK3.
A, B ZR-75-1 and CAMA-1 cell lines were treated with 1 lM MK-2206 or 1 lM AZD5363 for the indicated time periods. Cell lysates were subjected to (A) immunoblot
analysis with the indicated antibodies or (B) mRNA isolation followed by cDNA preparation. Real-time PCR was performed on cDNA samples using specific primers
against SGK1, SGK2 and SGK3 isoforms. Relative mRNA levels were calculated using 2(DD) Ct method using DMSO-treated samples as a calibrator. Results are
presented as relative mRNA level means  SD for triplicates.
C ZR-75-1 and CAMA-1 cells were treated with 1 lM MK-2206 or 1 lM AZD5363 for one hour (1 h) or 10 days. After 7-day treatment, SGK3 was knocked down by
using three different shRNA probes, named SGK3 A, B and C and compared to a control shRNA probe, named sh scramble. Cells were maintained in the presence or
absence of the indicated inhibitor during this period. At day 10, cells were lysed and subjected to immunoblot analysis with the indicated antibodies.
Source data are available online for this figure.
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inhibitor treatment (Fig 2A), prolonged treatment with Class I PI3K
inhibitors induced upregulation of SGK3 mRNA and protein levels
that was accompanied by an increase in NDRG1 phosphorylation
(Figs 2A and EV1). The induction of SGK3 protein and mRNA levels
was more pronounced in ZR-75-1 or CAMA-1 cells than T47D cells,
but nevertheless in all 3 cell lines, prolonged treatment with Class I
PI3K or Akt inhibitors induced a similar significant increase in
NDRG1 phosphorylation.
Prolonged treatment with Class I PI3K and Akt inhibitors leads to
activation of SGK3
To study the effect that Class I PI3K (GDC0941 and BKM120) and
Akt inhibitors (MK-2206 and AZD5363) had on SGK3 kinase activ-
ity, we immunoprecipitated endogenous SGK3 and assessed protein
kinase activity by measuring phosphorylation of the Crosstide
substrate peptide (Bago et al, 2014). In all cell lines tested (ZR-75-1,
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Figure 2. Prolonged treatment with Class I PI3K inhibitors leads to upregulation of SGK3.
A The indicated cell lines were treated with either 1 lM MK-2206, 1 lM AZD5363, 1 lM GDC0941 or 1 lM BKM120 for the indicated times. Cell lysates were subjected
to immunoblot analysis with the indicated antibodies.
B The indicated cells were treated as in (A) and SGK3 was immunoprecipitated from the lysates using an anti-SGK3 antibody. The immunoprecipitates (IP) were
subjected to in vitro kinase assay by measuring phosphorylation of the Crosstide substrate peptide in the presence of 0.1 mM [c-32P]ATP in a 30 min 30°C reaction
(upper panel) followed by immunoblot analysis with the indicated antibodies (lower panel). Kinase reactions are presented as means  SD for triplicate reaction.
Source data are available online for this figure.
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CAMA1 and T47D), short-term treatment (1 h) with Akt and Class I
PI3K inhibitors induced transient reduction in SGK3 activity without
affecting SGK3 protein levels. The underlying mechanism behind
this is not clear. In both ZR-75-1 and CAMA-1 cells, prolonged treat-
ment (5 days) with Class I PI3K or Akt inhibitors induced a robust
2- to 4-fold increase in SGK3 protein kinase activity (Fig 2B). More
moderate increases of SGK3 phosphorylation and activity was
observed in T47D cells, consistent with the lower induction of SGK3
(Fig 2A). Immunoblot analysis of SGK3 immunoprecipitates con-
firmed that prolonged treatment with Class I PI3K or Akt inhibitors
increased SGK3 protein as well as T-loop and hydrophobic motif
phosphorylation (Fig 2B).
Class III PI3K, hVps34, controls SGK3 activity
To explore the role that hVps34 might play in regulating endoge-
nous activity of SGK3 induced by prolonged treatment with Akt
inhibitors, we treated ZR-75-1 cells for 5 days with MK-2206 and
then incubated cells for 1 h with increasing doses of highly selective
and structurally diverse hVps34 inhibitors, namely VPS34-IN1 (Bago
et al, 2014) or SAR405 (Ronan et al, 2014). In ZR-75-1 cells pre-
treated with Akt inhibitor (MK-2206) for 5 days, both inhibitors
induced a dose-dependent inhibition of NDRG1 phosphorylation
with VPS34-IN1 reducing NDRG1 phosphorylation to basal levels at
1 lM (Fig 3A) and SAR405 at 0.3 lM (Fig EV2A), consistent with
the higher potency of SAR405 inhibitor towards hVps34 (Bago et al,
2014; Ronan et al, 2014). In agreement with VPS34-IN1 or SAR405
having no inhibitory activity towards Class I PI3K, neither
compound suppressed Akt phosphorylation nor PRAS40 phosphory-
lation (Figs 3B and EV2B). Elevated SGK3 protein kinase activity as
well as T-loop and hydrophobic motif phosphorylation induced by
prolonged treatment with Class I PI3K or Akt inhibitors was also
suppressed by treatment with 1 lM VPS34-IN1 (Fig 3C) or 0.3 lM
SAR405 (Fig EV2C). Treatment of ZR-75-1 cells cultured in serum
for 1 h with 1 lM VPS34-IN1 (Fig 3C) or 0.3 lM SAR405
(Fig EV2C) also reduced the basal SGK3 activity and phosphoryla-
tion detected in these cells to below control levels.
mTORC2 regulates activation of SGK3 downstream of hVps34
The identity of the hydrophobic motif kinase that phosphorylates
SGK3 downstream of hVps34 has not been established. Since
mTORC2 regulates activation of SGK1 (Garcia-Martinez & Alessi,
2008), we wished to explore whether mTORC2 also mediates SGK3
hydrophobic motif phosphorylation under conditions of prolonged
treatment with Class I PI3K or Akt inhibitors. To achieve this, we
generated ZR-75-1 cells in which the Rictor subunit of mTORC2
(Sarbassov et al, 2005) was knock down by ~90% employing an
shRNA approach (Fig 3D). Consistent with efficient knockdown of
Rictor and suppression of mTORC2 activity, Akt Ser473 phosphory-
lation was markedly reduced in the Rictor shRNA knockdown cells,
whereas phosphorylation of S6 protein, which is controlled in a
Rictor-independent manner by mTORC1, was unaffected (Fig 3D).
Knockdown of Rictor also virtually ablated kinase activity as well as
the hydrophobic motif phosphorylation of SGK3 induced by
prolonged treatment with Class I or Akt kinase inhibitors (Fig 3D).
Treatment of ZR-75-1 cells with the mTOR catalytic inhibitor
AZD8055 that inhibits both mTORC1 and mTORC2 suppressed
SGK3 hydrophobic motif and T-loop phosphorylation as well as
SGK3 kinase activity (Fig 3E). However, mTORC1 specific inhibitor
rapamycin that does not inhibit mTORC2 at this concentration had
no effect on SGK3 phosphorylation or activity (Fig 3E).
PtdIns(3)P promotes phosphorylation and activation of SGK3
by PDK1
To investigate whether PtdIns(3)P that is produced by hVps34
could promote phosphorylation and activation of SGK3, we
utilised recombinant SGK3[S486E], in which the hydrophobic
motif was mutated to Glu to mimic mTORC2 phosphorylation and
promote phosphorylation by PDK1 (Biondi et al, 2001). SGK3
[S486E] was purified from HEK293 cells that had been treated
with hVps34 (VPS34-IN1, 5 lM) and PDK1 inhibitor
(GSK2334470, 5 lM) (Najafov et al, 2011) for 1 h, to ensure that
SGK3 was in its dephosphorylated and inactive form. SGK3
[S486E] purified in this manner was incubated with lipid vesicles
comprising phosphatidylcholine (PC) and phosphatidylserine (PS)
containing either increasing concentrations of PtdIns(3)P or
PtdIns. Kinase reactions were initiated by the addition of PDK1
and MgATP. Activation of SGK3[S486E] was assessed by monitor-
ing phosphorylation of SGK3 at Thr320 (PDK1 site) and NDRG1
at Thr346 (SGK1 site). These studies revealed that activation of
SGK3[S486E] beyond background levels was only observed in the
presence of PS/PS vesicles containing PtdIns(3)P (Fig 4A). Even
Figure 3. SGK3 activity induced by inhibition of PI3K/Akt is regulated by hVps34 and mTORC2.
A ZR-75-1 cells were treated with 1 lM MK-2206 for 5 days and then, 1 h prior to cell lysis, cells were further treated with increasing doses of VPS34-IN1. Cell lysates
were subjected to immunoblot analysis with the indicated antibodies.
B ZR-75-1 cells cultured in serum in the absence of Akt inhibitor were treated for 1 h with the indicated concentrations of VPS34-IN1. The cell lysates were analysed by
immunoblot using the indicated antibodies.
C ZR-75-1 cells were treated for 5 days with either 1 lM MK-2206, 1 lM AZD5363, 1 lM GDC0941 or 1 lM BKM120. One hour prior to lysis, the cells were incubated in
the presence or absence of 1 lM VPS34-IN1. SGK3 was immunoprecipitated from lysates and subjected to in vitro kinase assay by measuring phosphorylation of the
Crosstide substrate peptide in the presence of 0.1 mM [c-32P]ATP in a 30 min 30°C reaction (upper panel). Kinase reactions are presented as means  SD for
triplicate reaction. Immunoprecipitates (IP) and lysates were analysed by immunoblot with the indicated antibodies. One-hour (1-h) treatment with the PDK1
inhibitor GSK2334470 (Najafov et al, 2011) (1 lM) was used as a control for SGK3 inhibition.
D ZR-75-1 cells were stably transfected with either a control shRNA vector (scrambled) or a shRNA vector that targets Rictor expression (shRictor). The cells were grown
in the presence or absence of 1 lM MK-2206 or 1 lM GDC0941 for 5 days. SGK3 was immunoprecipitated from the lysates and subjected to in vitro kinase assay as
in (C). Kinase reactions are presented as means  SD for triplicate reaction. Immunoprecipitates (IP) and lysates (lower panel) were also subjected to immunoblot
analysis with the indicated antibodies.
E ZR-75-1 cells were cultured in the absence or presence of 1 lM MK-2206 for 5 days. Cells were then treated in the absence or presence of 0.1 lM AZD8055 or 0.1 lM
rapamycin for 1 h. SGK3 was immunoprecipitated and subjected to in vitro kinase assay as in (C). Kinase reactions are presented as means  SD for triplicate
reaction. The immunoprecipitates (IP) and lysates were analysed with the indicated antibodies.
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at the highest concentration of PtdIns tested (10 lM), no signifi-
cant activation of SGK3[S486E] beyond control levels was
observed. We found that SGK3[S486E] isolated from HEK293 cells
was contaminated with endogenous PDK1 (high exposure immu-
noblot, see Fig 4), which is consistent with the ability of SGK3
[S486E] to bind PDK1 with high affinity (Biondi et al, 2001).
Therefore, even in the absence of added recombinant PDK1, incu-
bation of SGK3[S486E] with PC/PS vesicles containing PtdIns(3)P
and MgATP leads to partial activation, under conditions where no
detectable activation is observed when PtdIns(3)P is replaced with
PtdIns (Fig 4B). Addition of 50 ng recombinant PDK1 led to
further activation of SGK3[S486E] in the presence of PtdIns(3)P
but not PtdIns (Fig 4B). Mutation of PX domain residue Arg90,
required for interaction of SGK3 with PtdIns(3)P (Bago et al,
2014), suppressed activation of SGK3[S486E] by PDK1 in the
presence of PtdIns(3)P (Fig 4B).
14h is a potent inhibitor of SGK3
Recently, Sanofi published a new series of SGK1 inhibitors (Halland
et al, 2015). As the potency of these compounds towards the SGK3
isoform was not reported, we synthesised and evaluated the selec-
tivity of the four most potent SGK1 inhibitors (14g, 14h, 14i and
14n) described in this study (Fig 5A and Appendix Fig S1A). We
B
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A
Figure 4. PtdIns(3)P binding to PX domain of SGK3 promotes phosphorylation and activation by PDK1.
A, B SGK3 [S486E]-GST and SGK3 [R90A S486]-GST were purified from HEK293 cells transiently overexpressing these enzymes. One hour prior to lysis, cells were treated
with 5 lM VPS34-IN1 and 5 lM GSK2334470 to ensure that the SGK3 was in its inactive dephosphorylated form. SGK3[S486E]-GST (A) or the non-PtdIns(3)P-
binding mutant SGK3[R90A, S486E]-GST (B) was incubated with lipid vesicles comprising phosphatidylcholine (PC) and phosphatidylserine (PS) containing the
indicted concentrations of PtdIns or PtdIns(3)P in the presence or absence of added recombinant PDK1 (50 ng) and kinase reactions were initiated by addition of
MgATP. After 30 min at 30°C, PDK1 was inhibited by addition of the 1 lM GSK2334470 PDK1 inhibitor and the reaction mixture was supplemented with 2 lg GST-
NDRG1 SGK3 substrate. After another 30 min at 30°C, the reaction was terminated by addition of SDS sample buffer. The reaction mixtures were subjected to
immunoblot analysis with the indicated antibodies.
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confirmed that these compounds inhibited SGK1 with an IC50 of
10–70 nM and found that these compounds also targeted SGK3 with
an IC50 of 4–80 nM (Fig 5B and Appendix Fig S1B). The 14h inhi-
bitor was the most potent against SGK3, displaying an IC50 of 4 nM,
which is 2.5-fold more potent than it inhibits SGK1 (10 nM)
(Fig 5B). The selectivity of these inhibitors was assessed using the
Dundee panel of 140 kinases (Fig 5C for 14h and Appendix Fig S2
for 14g, 14i and 14n and Appendix Tables S1–S4). All four SGK
inhibitors displayed similar selectivity with the major off-target
kinases being S6K1, MLK1, MLK3 and TIE2 (Fig 5C for 14h and
Appendix Fig S2 for 14g, 14i and 14n and Appendix Tables S1–S4).
We observed that the SGK inhibitors (14g, 14h, 14i and 14n) also
suppressed S6K1 with IC50 of 55–180 nM and MLK isoforms with
IC50 of 94–600 nM (Fig 5B and Appendix Fig S1B). Importantly,
none of the SGK inhibitors tested significantly inhibited Akt1,
suggesting that these compounds would be useful in discriminating
between Akt- and SGK-mediated responses in vivo (Fig 5B and
Appendix Fig S1B).
14h suppresses NDRG1 phosphorylation in cells
For cellular experiments, we employed 14h, as it was the most
potent SGK3 inhibitor (Fig 5B). Treatment of ZR-75-1 cells cultured
in serum with increasing doses of 14h for 1 h resulted in a dose-
dependent decrease in NDRG1 phosphorylation. NDRG1 phosphory-
lation was maximally suppressed at 1–3 lM 14h, under conditions
where Akt-specific substrate PRAS40 was not dephosphorylated.
Consistent with the ~20-fold lower potency of 14h towards S6K1
compared to SGK3 (Fig 5B), 1–3 lM 14h failed to significantly
inhibit Rictor (Thr1135, S6K1 specific site) and S6 protein (Ser240/
244, S6K1 site) phosphorylation (Fig 5D). However, at 10 lM 14h,
we noticed a moderate reduction in S6K1 and S6 protein phosphory-
lation (Fig 5D), suggesting that 14h should not be deployed at
concentrations of higher than 3 lM in cellular studies.
14h suppresses T-loop and hydrophobic motif phosphorylation
of SGK3
Allosteric Akt inhibitors such as MK-2206, in addition to suppress-
ing kinase activity, also inhibit phosphorylation of the T-loop and
hydrophobic motifs by trapping Akt in a conformation that cannot
be phosphorylated by PDK1 and mTORC2 in cells (Green et al,
2008; Hirai et al, 2010). To determine whether 14h was capable of
suppressing SGK3 activation in an analogous manner, we treated
ZR-75-1 cells with increasing doses of 14h for 1 h and analysed after
immunoprecipitation SGK3 the T-loop and hydrophobic motif phos-
phorylation as well as kinase activity. This revealed that 14h
suppressed in a dose-dependent manner SGK3 hydrophobic as well
as T-loop phosphorylation resulting in reduced SGK3 activity
(Fig 5E). At 0.1 lM 14h, SGK3 activity and phosphorylation were
reduced by ~80% and undetectable by 1 lM (Fig 5E). In biochemi-
cal studies, 14h also suppressed the ability of PDK1 to phosphory-
late SGK3[S486E] at Thr320 in the presence of PtdIns(3)P, with a
near maximal inhibition observed at 0.1 lM 14h (Fig 5F).
SGK3 activates mTORC1 independently of Akt by
phosphorylating TSC2
We next treated ZR-75-1 cells with the MK-2206 Akt inhibitor for
between 1 h and 5 days and at intervals measured SGK3 and S6K1
catalytic activity (Fig 6). After 1-h treatment with MK-2206 (under
conditions where SGK3 activity remains low), ~10-fold reduction of
S6K1 activity was observed, which was accompanied by dephospho-
rylation of Rictor (Thr1135) and S6 protein (Ser240/244) as well as
4EBP1 (Ser65), another key substrate of mTORC1 (Fig 6). This
result is consistent with previous work showing that a major
substrate of Akt phosphorylation in cancer cells is the tuberous scle-
rosis complex protein TSC2 (Manning et al, 2002; Menon et al,
2014), which subsequently inhibits GTPase activating protein activ-
ity of TSC2, leading to the activation of the Rheb GTPase and hence
mTORC1 (Manning et al, 2002; Menon et al, 2014). Consistent with
this, 1-h treatment with MK-2206 induced dephosphorylation of
TSC2 (Ser939, Thr1462) at the sites phosphorylated by Akt.
However, after 1–2 days of MK-2206 treatment, as SGK3 is specifi-
cally becoming upregulated, we observed a commensurate increase
of S6K1 activity that correlates with increased phosphorylation of
TSC2 at the Akt sites as well as Rictor, S6 protein and 4EBP1 phos-
phorylation, under conditions which Akt remains inactivated
(Fig 6). After 4–5 days MK-2206 treatment, S6K1 activity as well as
the phosphorylation of TSC2, Rictor, S6 protein and 4EBP1 had
recovered to the similar level that was observed in non-Akt
inhibitor-treated cells (Fig 6).
As Akt and SGK isoforms have very similar substrate specificity
(Murray et al, 2005), our data indicate that SGK3 might functionally
substitute for Akt in phosphorylating TSC2 in cells lacking Akt activ-
ity. To investigate this further, we treated ZR-75-1 cells for 5 days
with either Class I PI3K (GDC0941) or Akt (MK-2206) inhibitors and
investigated the effect that the 14h inhibitor had on TSC2, S6K1,
Figure 5. 14h selectively suppresses both the activity and activation of SGK3 by PDK1 and mTORC2.
A Chemical structure of the Sanofi-14h SGK inhibitor.
B IC50 values of Sanofi-14h SGK inhibitor on the indicated recombinant kinases.
C Protein kinase profiling undertaken against the Dundee panel of 140 protein kinases in the presence of 1 lM Sanofi-14h at the International Centre for Protein
Kinase Profiling. The result for each kinase is presented as a mean kinase activity of the reaction taken in triplicate relative to a control reaction where the inhibitors
were omitted. Abbreviations and assay conditions are described at http://www.kinase-screen.mrc.ac.uk.
D ZR-75-1 cells were treated for 1 h with the indicated concentrations of 14h. The cell lysates were analysed by immunoblot analysis using the indicated antibodies.
E ZR-75-1 cells were treated for 1 h with the indicated concentrations of 14h. SGK3 was immunoprecipitated from cell lysates and subjected to in vitro kinase assay by
measuring phosphorylation of the Crosstide substrate peptide in the presence of 0.1 mM [c-32P]ATP in a 30 min 30°C reaction (upper panel). Kinase reactions are
presented as means  SD for triplicate reaction. Immunoprecipitates (IP) were also analysed by immunoblot with the indicated antibodies.
F The effect of the indicated concentration of 14h on the ability of SGK3[S486E]-GST to be activated by PDK1 in the presence of PtdIns(3)P was assessed as described in
Fig 4.
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Rictor, S6 protein and 4EBP1 phosphorylation (Fig 7). Consistent
with SGK3 mediating phosphorylation of TSC2 and leading to the
activation of mTORC1 under these conditions, we observed that
treatment with 3 lM 14h for 1 h suppressed phosphorylation
of TSC2. We also observed suppression of activity and phosphoryla-
tion of S6K1 and its downstream targets, Rictor and S6
protein (Fig 7A and B). However, phosphorylation of 4EBP1, other
mTORC1 substrate, was not markedly reduced upon SGK3
inhibition (Fig 7A). In contrast, 14h did not inhibit TSC2, S6K1,
Rictor, S6 protein or 4EBP1 phosphorylation or S6K1 activity in
ZR-75-1 cells cultured in serum in the absence of prolonged treat-
ment with PI3K or Akt inhibitors (Fig 7A and B). As expected, under
these conditions, Class I PI3K or Akt inhibitors suppressed TSC2,
S6K1, Rictor, S6 protein or 4EBP1 protein phosphorylation as well
as S6K1 activity (Fig 7A) and addition of SGK inhibitor (14h) failed
to ablate dephosphorylation of these substrates (Fig EV3A). To
further evaluate impact of SGK3 inhibition, we performed shRNA-
mediated knockdown of SGK3 expression in ZR-75-1 cells treated in
the presence or absence of the Akt (MK-2206) inhibitor for 1 h or
5 days (Fig 7C). This revealed that knockdown of SGK3 markedly
reduced phosphorylation of NDRG1 as well as TSC2, leading to an
inhibition of mTORC1, reflected by the inhibition of S6K1, Rictor, S6
protein and 4EBP1 phosphorylation when compared to scrambled
shRNA control samples (Fig 7C).
We also tested whether the addition of hVps34 inhibitor (VPS34-
N1) would have the same suppressive effect on phosphorylation of
TSC2 and mTORC1 substrates as SGK3 inhibition (Fig EV3B). We
found that addition of 1 lM VPS34-IN1 for 1 h after prolonged treat-
ment with Akt (MK-2206) or Class I PI3K (GDC0941) inhibitors had
a similar effect as SGK3 inhibition (Fig EV3B). We observed reduced
phosphorylation of TSC2, S6K1, Rictor, S6 protein and 4EBP1
(Fig EV3B). Treatment of ZR-75-1 cells for 1 h with 1 lM of VPS34-
IN1 alone under conditions which SGK3 is not activated did not
have an effect on TSC2 or mTORC1 substrate phosphorylation.
To explore whether any other potential SGK3 phospho-substrates
could be detected, we treated ZR-75-1 cells for 1 h or 5 days with
Akt inhibitor (MK-2206) or Class I PI3K (GDC0941) in the presence
or absence of SGK3 inhibitor (14h) for 1 h prior to lysis. Lysates
were immunobloted with anti-p-Akt motif substrate antibody
(RxRxxpS/pT) (Zhang et al, 2002). The results revealed that at
least 6 Akt substrates detected by the p-Akt motif antibody were
re-phosphorylated on Akt phosphorylation consensus motif after a
5-day exposure to Akt (MK-2206) or Class I PI3K (GDC0941) inhibi-
tors when SGK3 is upregulated, in a manner that was blocked by
the 14h SGK3 inhibitor (Fig EV3C). We also observed 3 Akt
substrates that were not re-phosphorylated on Akt phosphorylation
consensus motif after a 5-day exposure to MK-2206/GDC0941 when
SGK3 is upregulated, suggesting these are Akt selective (like
PRAS40). No evidence of any SGK3 selective substrates recognised
by the p-Akt motif antibody was observed (Fig EV3C).
Combined inhibition of both Akt and SGK is required to regress
BT-474 xenograft tumours
In order to establish the therapeutic potential of combined AKT and
SGK3 inhibition in a breast cancer model, we tested cell prolifera-
tion in vitro and established xenografts in nude mice with BT-474
cells, which are sensitive to Akt inhibitors when cultured in vitro
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Figure 6. SGK3 counteracts inhibition of the PI3K/Akt pathway by
phosphorylating TSC2 and stimulating S6K1.
ZR-75-1 cells were treated with 1 lM MK-2206 for the indicated times. SGK3
(upper panel) and S6K1 (middle panel) were immunoprecipitated and subjected
to in vitro kinase assay by measuring phosphorylation of the Crosstide substrate
peptide in the presence of 0.1 mM [c-32P]ATP in a 30 min 30°C reaction. Kinase
reactions are presented as means  SD for triplicate reaction.
Immunoprecipitates (IP) were also analysed by immunoblot with the indicated
antibodies. The cell lysates were also analysed by immunoblot using the
indicated antibodies (lower panel).
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(Sommer et al, 2013) and in which prolonged treatment with Akt
inhibitors leads to upregulation of SGK3 (Fig 8A). Measurement of
cell confluency over 5–6 days in the continued presence of the Akt
inhibitors, MK2206 or AZD5363, revealed a dose-dependent inhibi-
tion of cell growth compared to DMSO-treated cells (Fig 8B upper
and bottom panel and Fig EV4A and B). Treatment with SGK inhi-
bitor (14h) alone had little anti-proliferative effect, even at 3 lM
concentration (Fig 8B upper and bottom panel and Fig EV4A and B).
To determine whether a combination effect could be observed
following prolonged inhibition of Akt, a long-term growth assay was
undertaken. Culture in the presence of 0.3 lM Akt inhibitors
(AZD5363 or MK-2206) dramatically slowed the growth of BT-474c
cells but they eventually reached confluency after approximately 24
and 20 days, respectively. Addition of 3 lM SGK inhibitor (14h)
induced further reduction in cell growth when it was combined with
Akt inhibitor (AZD5363 or MK-2206) from the beginning of treat-
ment or added sequentially 12 days after initial administration of
Akt inhibitor (AZD5363 or MK-2206) alone (Fig 8B, upper and
bottom panel).
The anti-tumour efficacy of the Akt (MK-2206) and SGK (14h)
inhibitors as monotherapy and in combination was investigated in
the BT-474 human breast xenograft model. At 100 mg/kg MK-2206,
the in vivo growth of BT-474 was inhibited at ~20% (P < 0.01);
however, no regression as monotherapy was observed. No
anti-tumour effects were observed following treatment with the SGK
inhibitor alone (14h, 25 mg/kg). However, concomitant administra-
tion of both agents had a significantly greater effect than that
observed with either agent alone, including ~80% regression in all
tumours (P < 0.001). No toxicity or weight loss relative to the vehi-
cle control group was observed in any treatment group (Fig 8D).
The concentration of inhibitors in the plasma measured 2–3 h after
the final administration was 1–3 lM (Fig 8E), without significant
differences when administered as a monotherapy or combination.
To evaluate whether tumour regression in combination treatment
was due to apoptosis, we performed immunohistochemical analysis
of tumour samples with anti-cleaved caspase-3 antibodies. Results
showed increased number of apoptotic cells in Akt inhibitor (MK-
2206) monotreatment as compared to vehicle treatment, and the
number of apoptotic cells was significantly higher (P < 0.001) in
combination (MK-2206 and 14h) treatment compared to MK-2206
treatment alone (Fig 8F). Taken together, these data indicate that
inhibition of both Akt and SGK is required to achieve superior anti-
tumour activity in these xenografts.
To elucidate possible mechanisms for anti-proliferative effect
with SGK and Akt inhibitor combination treatment in in vitro and
in vivo experiments, we analysed tumour samples taken at the
end of the treatment. Immunohistochemical and immunoblot anal-
ysis revealed that Akt inhibitor (MK-2206) alone ablated Akt 473
and PRAS40 phosphorylation and partially reduced NDRG1 phos-
phorylation and S6 protein phosphorylation (Fig 8G and H). SGK
inhibitor (14h) when administered alone had no major effect on
phosphorylation of any of these markers (Fig 8G and H). Combi-
nation of Akt and SGK inhibitors (MK-2206 and 14h) resulted in
the ablation of NDRG1 phosphorylation and a more moderate
inhibition of S6 protein phosphorylation than was observed with
MK-2206 inhibitor alone (Fig 8G and H). Immunoblot analysis also
revealed that SGK3 protein level was not markedly upregulated in
tumours of mice treated with either Akt inhibitor (MK-2206) alone
or in combination with SGK3 inhibitor (14h). However, the phos-
phorylation of NDRG (Thr246) was not ablated in Akt inhibitor
treatment, indicating higher SGK3 activity, whereas combination
treatment (MK-2206 and 14h) induced marked dephosphorylation
Figure 7. SGK3 counteracts inhibition of the PI3K/Akt pathway by phosphorylating TSC2 and stimulating mTORC1.
ZR-75-1 cells were treated for 1 h or 5 days with 1 lM MK-2206, 1 lM GDC0941 or 3 lM 14h inhibitors, alone or in combination, as indicated.
A The cell lysates were analysed by immunoblot using the indicated antibodies.
B SGK3 (upper panel), Akt1 (middle panel) and S6K1 (lower panel) were immunoprecipitated from the same cell lysates and subjected to in vitro kinase assay by
measuring phosphorylation of the Crosstide substrate peptide for kinases in the presence of 0.1 mM [c-32P]ATP in a 30 min, 30°C reaction. Kinase reactions are
presented as means  SD for triplicate reaction. Immunoprecipitates (IP) were also analysed by immunoblot with the indicated antibodies.
C SGK3 was knocked down in ZR-75-1 cells by using shRNA probe B and compared to a control shRNA probe, named sh scramble. After infection, the cells were kept for
2 days in puromycin selection media and then seeded for the experiment. The cells were treated with 1 lM MK-2206 for 1 h or 5 days. The cell lysates were
subjected to immunoblot analysis with the indicated antibodies.
Figure 8. Dual treatment with Akt and SGK inhibitors reduces tumour growth in BT-474 xenograft model.
A BT-474 cells were treated for the indicated times with 0.3 lM MK-2206. The cell lysates were analysed by immunoblot using the indicated antibodies.
B BT-474c cells were treated with inhibitors as indicated either as monotherapy or in combination and cell confluency measured on the Incucyte ZOOM every 4 h for
up to 4 weeks.
C BT-474 cells were injected subcutaneously into athymic Foxn1nu nude mice. Mice were treated with either vehicle (8 mice) or MK-2206 (100 mg/kg) (10 mice) or 14h
(25 mg/kg) (6 mice) or both, MK-2206 and 14h (10 mice) for 24 days. The tumour volume was measured twice a week. Tumour growth is represented as the fold
change mean  SEM.
D All mice were weighed at the end of the treatments. Results are presented as mean  SD.
E Plasma concentrations of MK-2206 and 14h were analysed in samples obtained 2–3 h after the administration of the last dose on the 24th day of treatment. Results
are presented as a mean  SD from three different samples.
F Tumours were harvested at the end of the experiment, 4 h after the last dosage and subjected to immunohistochemical analysis using cleaved caspase-3 antibody
(clCasp3). Apoptotic cells were counted in 25 fields per condition (left panel) and quantified as clCasp3-positive cells/field (right panel). The results are presented as
mean  SD number of cleaved caspase-3 positive cells. Representative images are shown. Scale bar, 100 lm.
G Tumours were harvested at the end of the experiment, 4 h after the last dosage and subjected to immunohistochemical analysis with the indicated antibodies.
Representative images are shown. Scale bar, 100 lm.
H Tumours were obtained the same way as in (G) and subjected to immunoblot analysis with the indicated antibodies. Six different tumours were analysed from each
treatment group and each line represents one tumour sample.
◀
▸
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of NDRG1 (Fig 8H). Additionally, phosphorylation of S6K1
(Thr389), S6 (Ser240/244) and 4EBP1 (Ser65) was detectable in
samples of mice treated with Akt inhibitor (MK-2206) alone,
whilst they were severely diminished in samples of mice receiving
combination treatment (Fig 8H). These results indicate possible
reactivation of the mTORC1 pathway after monotreatment with
the Akt inhibitor (MK-2206). However, it is not clear whether the
reactivation was mediated through SGK3 phosphorylating TSC2 at
Akt sites (Thr1462), since the tumour samples obtained from
monotreated (MK-2206) or combination (MK-2206 and 14h) mice
showed similar level of TSC2 phosphorylation (Fig 8H). Further
analysis of BT-474c cell line treated for 5 days with Akt inhibitor
(MK-2206) and subsequent 1-h treatment with SGK3 inhibitor
(14h) showed the similar results as observed in ZR-75-1 cells. We
observed suppression of phosphorylation of TSC2, S6K1 and its
downstream target S6 protein (Fig EV4C). Phosphorylation of
4EBP1 was not markedly reduced upon SGK3 inhibition
(Fig EV4C). SGK inhibitor (14h) did not significantly suppress
phosphorylation of TSC2, S6K1, S6 protein or 4EBP1 in BT-474c
cells cultured in serum in the absence of prolonged treatment with
Akt inhibitor (Fig EV4C).
Exploitation of digital barcoding technology to quantify human
kinome mRNA after inhibitor exposure
Given the profound effects of prolonged treatment with Akt and
Class I PI3K inhibitors on SGK3 mRNA in cells, we next quantified
the effects of MK-2206, AZD5363 and GDC0941 across the complete
human protein kinase superfamily (Table EV1). To accomplish this,
we employed NanoString technology (Geiss et al, 2008) to digitally
capture dynamics of the kinase transcriptome in response to all 3
compounds after 5 days of compound exposure (Fig 9). These data
revealed complex reprogramming signatures and the appearance of
compound-specific profiles. For example, exposure to MK-2206
(Fig 9A) and AZD5363 (Fig 9B) both promoted an increase in RET
and SGK110 (both from low basal levels), and a marked decrease in
CDK6 mRNA levels. In contrast, exposure to the PI3K inhibitor
GDC0941 (Fig 9C) induced a more generalised kinome-wide
increase in mRNA levels alongside a profound elevation in SGK3
mRNA. Indeed, out of the 536-member kinase panel, SGK3 mRNA
had increased to become the 48th highest level of expression by day
5, compared to 230th in the matched DMSO control, 94th in MK-2206
and 144th in AZD5363. In contrast, we found that PKCc mRNA
levels consistently decreased after exposure to all 3 inhibitors. These
data revealed that although SGK1 and SGK2 were expressed at
extremely low levels in ZR-75-1 cells (Table EV1), very small drug-
induced increases in SGK2 could be detected using a sensitive digital
assay (Table EV1). However, SGK2 increases were very low
compared to SGK3 (Table EV1), which had reached an expression
level equivalent to ~0.5% of the entire kinome mRNA after
GDC0941 exposure for 5 days.
The six human AKT and SGK protein kinases belong to the AGC
kinase subfamily. To evaluate specific effects of Akt/PI3K inhibitors
on the complete AGC family, we quantified actual and relative levels
of the 60 human AGC kinases in triplicate samples after exposure to
compounds for either 2 days (Appendix Fig S3) or 5 days
(Appendix Fig S4). SGK3 was consistently the most highly upregu-
lated AGC kinase mRNA after exposure to all 3 compounds.
Interestingly, the Akt inhibitors AZD5363 (2- to 3-fold upregulation)
or MK-2206 (4- to 5-fold upregulation) were less potent inducers of
SGK3 mRNA compared to GDC0941 (6- to 10-fold increase). Several
other AGC kinases, including RSKL2 and MSK1, also demonstrated
statistically significant upregulation in response to several of these
compounds (Appendix Figs S3 and S4). The AGC kinome data
set also provided the opportunity to assess relative absolute mRNA
levels. Interestingly, AKT1 and AKT2 mRNA levels were the highest
amongst all AGC kinases in ZR-75-1 cells under the conditions stud-
ied, consistent with a key endogenous pro-survival role. Consistent
with our previous findings, exposure of ZR-75-1 cells to these inhibi-
tors for either 2 or 5 days (Appendix Figs S3 and S4) had a specific
and profound effect on SGK3 mRNA content. For example, SGK3
mRNA represented only the 29th most highly expressed AGC kinase
in the presence of DMSO vehicle, but it had increased to become the
12th most highly abundant AGC kinase mRNA after exposure to MK-
2206 and the 7th most highly abundant after exposure to GDC0941.
Discussion
Akt isoforms play crucial roles in regulating survival and prolifer-
ation of cancer cells, and it would therefore be expected that loss
of Akt activity resulting from prolonged treatment with Class I
PI3K or Akt inhibitors would not be well tolerated. Such tumours
would thus be under great therapeutic pressure to upregulate
additional signalling pathways to compensate for this loss of Akt
activity. The ability to rapidly upregulate the SGK3 pathway
represents an ingenious solution not only because SGK3 possesses
similar substrate specificity as Akt and hence the ability to phos-
phorylate at least a subset of overlapping substrates but also
because SGK3 can be activated independently of Class I PI3K via
hVps34. Therefore, upregulation of SGK3, which we observed in
our models of Akt-sensitive breast cancer cell lines, could serve
as a strategy to circumvent inhibition of Class I PI3K as well as
Akt isoforms and provide adaptive resistance response. Indeed,
immunoblot analysis of ZR-75-1 total cell extracts employing the
p-Akt motif antibody suggested that 6 out of the 9 detected Akt
substrates are likely to be phosphorylated by both Akt and SGK3
(Fig EV3C).
By virtue of its PX domain, SGK3 is capable of binding to
PtdIns(3)P produced by hVps34 on the endosomes (Bago et al,
2014) and our biochemical data suggest that PtdIns(3)P binding
can directly promote phosphorylation and activation of SGK3 by
PDK1 (Fig 4). However, it has also been reported that metabolism
of PtdIns(3,4,5)P3 to PtdIns(3)P at the plasma membrane via the
consecutive actions of the SHIP2 and INPP4A/B inositol phos-
phatases can activate SGK3, and these conclusions are partially
based on the findings that Class I PI3K inhibitors suppress SGK3
activity (Fig 2B) (Gasser et al, 2014; Chi et al, 2015). SGK3 is also
partially suppressed by treatment with Class I PI3K inhibitors in
U2OS cells (Bago et al, 2014). In our opinion, it has not yet been
possible to rule out whether the effect of Class I PI3K inhibitors
on SGK3 activity is a consequence of these compounds inhibiting
the activation of mTORC2 that triggers SGK3 activation by phos-
phorylating the hydrophobic motif rather than an effect on plasma
membrane PtdIns(3)P levels generated via metabolism of PtdIns
(3,4,5)P3.
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Figure 9. Prolonged exposure to Akt or Class I PI3K inhibitors induces transcriptional changes in human kinome.
A–C ZR-75-1 cells were treated for 5 days with 1 lM MK-2206 (A), 1 lM AZD5363 (B), 1 lM GDC0941 (C) or DMSO. Human mRNAs were hybridised to NanoString
human kinome and control code sets, then subjected to quantification using NanoString software. Results are presented as mRNA change of each kinase relative to
mRNA isolated from control sample treated with DMSO. To permit data compaction, and simple kinome-wide comparisons, the fold changes are log2 transformed.
The kinase mRNAs exhibiting prominent changes are annotated, with SGK3 highlighted in red. Similar profiles were obtained in second independent experiment.
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Other SGK isoforms (SGK1 or SGK2) do not possess a PX domain
and, like Akt, are activated downstream of Class I PI3K isoforms. It
would therefore be unlikely that SGK1 and SGK2 could substitute
for Akt in cells treated with Class I PI3K inhibitors, which may
explain why we did not observe marked upregulation of SGK1 or
SGK2 in the experiments we undertook (Figs 1 and 2). The
conserved emergence of SGK3 as a key inducible resistance determi-
nant might potentially be explained by the very high endogenous
levels of AKT1 and AKT2 expression already present in these cells,
and the almost complete absence of AKT3, SGK1 and SGK2 mRNAs
(Table EV1) as potential compensatory mechanisms for when Akt1
and Akt2 activity are blocked.
The SGK3 gene has been reported to be an oestrogen or
androgen receptor transcriptional target in ER-positive breast
cancer cells (Wang et al, 2011; Xu et al, 2012) and in androgen
receptor (AR)-positive prostate cancer (Wang et al, 2014). It
would be important to investigate the molecular mechanism by
which prolonged inhibition of Akt or Class I PI3K leads to
kinome-wide changes in mRNA expression levels, and in particu-
lar SGK3 mRNA and whether the upregulation of SGK3 protein
and activity is limited to ER/AR cell backgrounds/tumours, or
applicable to broader group of cancer cells. It would also be inter-
esting to perform kinome-wide mRNA profiling in a wide selection
of tumour or patient-derived cells before and after inhibitor
exposure, so that drug resistance signatures in addition to SGK3
can be compared and contrasted as potential guides to inform
targeted therapeutics.
The notion that SGK isoforms can play an important role in
controlling growth and proliferation is also supported by research
undertaken in model organisms such as Caenorhabditis elegans and
budding yeast. Studies in Caenorhabditis elegans reveal that SGK
rather than Akt is the key mediator of proliferation responses by
controlling fat metabolism, reproduction and lifespan (Jones et al,
2009; Soukas et al, 2009). In budding yeast, the SGK homologues
termed YPK1 and YPK2 also play a vital role in regulating metabolic
and other responses required for viability and proliferation
(Casamayor et al, 1999; Niles et al, 2012). Previous work has
shown that SGK3 is overexpressed in a variety of cancer cell lines
and knockdown of SGK3 in these cells including in ZR-75-1 cells
employed in this study has substantial impact on proliferation
(Virbasius et al, 2001; Gasser et al, 2014; Chi et al, 2015), results
we have been able to confirm (RB, data not shown).
Our data reveal that by phosphorylating TSC2 and activating
mTORC1, SGK3 can mediate what has previously been referred to
as “Akt-independent signalling” (Bruhn et al, 2010, 2013). It is
likely that in addition to TSC2, SGK3 will phosphorylate a group of
Akt substrates that could play important roles in driving metabolic,
transcription and translational responses needed for the survival
and proliferation of cancer cells. Consistent with this, 6 out of the 9
Akt substrates detected by immunoblot analysis of ZR-75-1 cell
extracts appear to be phosphorylated by both Akt and SGK3
(Fig EV3C). However, it should be noted that SGK3 does not phos-
phorylate PRAS40 (Thr246) or Foxo1 (Ser256) (Fig 6), indicating
that a subset of Akt substrates are not phosphorylated by SGK3. In
these studies, we did not detect any SGK3 selective substrates that
are not phosphorylated by Akt (Fig EV3C). Further work would be
required to understand the mechanisms determining which of the
Akt substrates can be phosphorylated by SGK3, as this could be
controlled by consensus motif sequences and/or cellular localisation
of the substrate.
We also noticed that under conditions of sustained Akt inhibition
in ZR-75-1 cells, in which SGK3 is activated, addition of SGK3 inhi-
bitor (14h) (Fig 7A), whilst suppressing S6K1 phosphorylation, failed
to commensurately reduce 4EBP1 phosphorylation. Similar results
have been observed in other cell lines treated with the mTORC1 inhi-
bitor rapamycin or starved from amino acids, where S6K1 phosphory-
lation was suppressed to a much greater extent than 4EBP1 (Choo
et al, 2008; Kang et al, 2013). Other mTORC1 substrates have also
been reported to be differentially affected following inhibition of
mTORC1 (Kang et al, 2013). It has been suggested that this results
from mTORC1 substrates being deferentially sensitive to residual
mTORC1 activity depending on the type and the duration of the stress
conditions (Kang et al, 2013). We have also observed that the hVps34
inhibition leads to a greater dephosphorylation of 4EBP-1 than seen
with SGK3 inhibition (Fig EV3B). This could be accounted for if the
inhibition of hVps34 led to suppression of mTORC1 through mecha-
nisms additional to SGK3. Indeed, several studies report regulation of
mTORC1/S6K1 by hVps34 in response to amino acid starvation
through an ill-defined mechanism (Byfield et al, 2005; Nobukuni
et al, 2005). We also observed that in BT-474c cells, the inhibition of
SGK3 induced a more moderate inhibition of S6K1 than in ZR-75-1
cells (Figs 6 and EV4C), indicating that there is likely to be variation
between cancer cell lines.
In this study, we have further characterised 14h, a novel
small-molecule cell-permeant SGK inhibitor initially reported by
Sanofi (Halland et al, 2015). 14h and the other related inhibitors
we have analysed (14g, 14i and 14n) are much more specific than
a previously reported and widely used SGK inhibitor GSK650394
(Sherk et al, 2008) that inhibits many kinases other than SGK1
(http://www.kinase-screen.mrc.ac.uk/screening-compounds/34880
7?order=field_results_inhibition&sort=asc). The only other rela-
tively selective SGK1 inhibitor that we are aware of, EMD638683
(http://www.kinase-screen.mrc.ac.uk/screening-compounds/61759
4), is not potent displaying an in vitro IC50 of only 3 lM
(Ackermann et al, 2011). Consistent with this, extremely high
doses of 100 lM EMD638683 are required to observe marginal
reduction in NDRG1 phosphorylation in breast cancer cells that
express high levels of SGK1 (Eeva Sommer, data not shown).
Our data demonstrate that 1–3 lM 14h optimally suppresses
SGK3-mediated phosphorylation of NDRG1 and TSC2 in cells
(Figs 5–7). We also observed that 14h in addition to inhibiting
SGK3 catalytic activity also suppressed phosphorylation of both
the T-loop and hydrophobic motif of SGK3 in cells (Fig 5E), as
well as inhibiting PDK1 from phosphorylating SGK3[S486E] in the
presence of PtdIns(3)P in vitro (Fig 5F). This is analogous to Akt
allosteric inhibitors such as MK-2206 that interact in an interface
between the PH domain and the kinase domain, trapping Akt in a
conformation that cannot be activated by PDK1 and mTORC2 (Green
et al, 2008; Calleja et al, 2009; Wu et al, 2010). 14h was expected to
function as a conventional Akt competitive inhibitor (Halland et al,
2015), so it is unusual for this compound to also work by preventing
the activation of SGK3 by its upstream activators.
The finding that the growth of BT-474 breast cancer cells in
in vitro and in a xenograft model is highly sensitive to a combina-
tion of Akt (MK-2206) and SGK (14h) inhibitors that induced inhibi-
tion of cell growth and tumour regression emphasises the
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therapeutic potential of a strategy of targeting both the Akt and SGK
kinases for the treatment of cancer. We cannot rule out that 14h has
off-target effects in a xenograft model and it would be critical to
repeat these studies with a structurally diverse SGK inhibitor when
it becomes available. Also, it would be useful to analyse the sensi-
tivity of a broader number of tumours to combinations of SGK and
Akt or Class I PI3K inhibitors.
In conclusion, our findings highlight the critical importance of
the hVps34-SGK3 pathway and reveal that this upregulated signal-
ling module represents a major mechanism that cells utilise to
counteract inhibition of the PI3K/Akt signalling network. SGK3 is
consistently the most highly upregulated kinase mRNA
amongst the 60 human AGC kinases evaluated in ZR-75-1 cells
exposed to either Class I PI3K or Akt inhibitors. Our findings also
reveal the hVps34-SGK3 signalling pathway operates as a PI3K/
Akt-independent network to stimulate mTORC1 and likely other
pathways that promote cancer growth. We demonstrate that
sustained suppression of Class I PI3K or Akt activity over several
days triggers the selective upregulation of SGK3 mRNA and protein
as well as its catalytic activity in a variety of breast cancer cell
lines. Our results suggest that SGK3 is specifically activated by the
hVps34 lipid kinase that generates PtdIns(3)P on endosomal
membranes. PtdIns(3)P then binds to the PX domain of SGK3,
promoting its phosphorylation and activation by PDK1. Our find-
ings indicate that once activated in cells that lack Akt activity,
SGK3 substitutes for Akt by phosphorylating TSC2 to trigger activa-
tion of mTORC1. Our characterisation of the 14h SGK inhibitor
suggests that it will become a useful research tool to probe signal-
ling responses controlled by SGK isoforms in vivo. 14h represents a
valuable addition to our growing armoury of signal transduction
inhibitors to dissect functional roles of protein kinases. Finally, we
establish that combined administration of Akt (MK-2206) and SGK
(14h) inhibitors to mice bearing xenograft BT-474 breast cancer
tumours induces a striking tumour regression compared to when
the inhibitors were administered individually. These findings high-
light the therapeutic potential of a strategy targeting both the Akt
and SGK kinases for the treatment of cancer.
Materials and Methods
Materials
Protein-G Sepharose, Glutathione-Sepharose (Amersham
Biosciences); [c-32P]ATP (Perkin Elmer); Triton X-100, EDTA,
EGTA, sodium orthovanadate, sodium glycerophosphate, sodium
fluoride, sodium pyrophosphate, 2-mercaptoethanol, sucrose,
benzamidine, Tween-20, Tris–HCl, sodium chloride, magnesium
acetate, DMSO, reduced glutathione (Sigma); phenylmethylsulfonyl
fluoride (PMSF) (Melford); tissue culture reagents, Novex 4–12%
Bis-Tris gels, NuPAGE LDS sample buffer 4× (Invitrogen); Ampi-
cillin (Merck); P81 phosphocellulose paper (Whatman); methanol
(VWR Chemicals). liver phosphatidylcholine, brain phosphatidylser-
ine, 1,2-dioleoyl-sn-glycero-3-(phosphoinositol-3-phosphate) and
1,2-dioleoyl-sn-glycero-3-phosphoinositol (Avanti Polar Lipids).
Inhibitors GDC0941 (Axon Medchem), BKM120 (ChemieTek), MK-
2206 (Selleck), GSK2334470 (Tocris), AZD8055 (Selleck) were
purchased from the indicated suppliers. AstraZeneca provided
AZD5363. VPS34-IN1 was synthesised as described in Bago et al
(2014). SAR405 (CAS: 1523406-39-4) was synthesised as described
in Ronan et al (2014). Sanofi compounds 14g, 14h, 14i and 14n
were synthesised as described previously (Halland et al, 2015). All
recombinant proteins, DNA constructs, antibodies and inhibitors
including VPS34-IN1 and SAR405 generated for the present study
are described and can be requested on our reagents website
(https://mrcppureagents.dundee.ac.uk/).
General methods
DNA procedures were undertaken using standard protocols. DNA
constructs were purified from E. coli DH5alpha using maxi prep kit
(Qiagen). DNA sequence of the DNA constructs used in this study
was performed by the Sequencing Service (MRC Protein Phosphory-
lation Unit, College of Life Sciences, University of Dundee, UK;
www.dnaseq.co.uk).
Antibodies
The following antibodies were raised in sheep, by the Division of
Signal Transduction Therapy (DSTT) at the University of Dundee,
and affinity purified against the indicated antigens: anti-Akt1
(S695B, third bleed; raised against residues 466–480 of human Akt1:
RPHFPQFSYSASGTA), anti-NDRG1 (S276B third bleed; raised
against full-length human NDRG1) (DU1557), anti-SGK3 (S037D
second bleed; raised against human SGK3 PX domain comprising
residues 1–130 of SGK3) (DU2034), anti-PDK1 (S682, third bleed;
raised against residues 544–556 of human PDK1: RQRYQSHP-
DAAVQ) and anti-S6K1 (S417B, 2nd bleed; raised against residues
25–44 of human S6K1: AGVFDIDLDQPEDAGSEDEL). Anti-phospho-
Akt Ser473 (#9271), anti-phospho-Akt Thr308 (#4056), anti-
phospho-NDRG1 Thr346 (#5482), anti-GAPDH (#2118),
anti-phospho-TSC2 Thr1462(#3617), anti-phospho-TSC2 Ser939
(#3615), anti-TSC2 (#3612), anti-phospho-Rictor Thr1135 (#3806),
anti-Rictor (#2140), anti-phospho-S6K1 Thr389 (#9205), anti-
phospho-rpS6 Ser240/244 (#2215), anti-phospho-rpS6 Ser235/36
(#4856), anti-rpS6 (#2217), anti-phospho-4EBP1 Ser65 (#9451), anti-
4EBP1 (#9452), anti-phospho-SGK3 Thr320 (#5642) and
anti-phospho-Akt substrate (RxRxxS/T) (#10001) antibodies were
purchased from Cell Signalling Technology. Anti-(phospho-SGK
hydrophobic motif [Ser486 in SGK3]) antibody (#sc16745) was from
Santa Cruz Biotechnology, and total anti-SGK antibody was from
Sigma (#5188). Secondary antibodies coupled to HRP (horseradish
peroxidase) were obtained from Thermo Scientific.
Cell culture and cell lysis
ZR-75-1, CAMA-1, T47D and BT-474c cell lines were sourced as
described previously (Davies et al, 2012). HEK293 cells were
purchased from the American Tissue Culture Collection (ATCC).
Cells were cultured in RPMI or DMEM media supplemented with
10% (v/v) foetal bovine serum, 2 mM L-glutamine, 100 U/ml
penicillin and 0.1 mg/ml streptomycin. Inhibitor treatments were
carried out as described in figure legends. During 5 days inhibitor
treatments, the media was changed after 72-h intervals. The cells
were lysed in buffer containing 50 mM Tris–HCl (pH 7.5),
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM sodium
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orthovanadate, 10 mM sodium glycerophosphate, 10 mM sodium
pyrophosphate, 0.27 M sucrose, 0.1% (v/v) 2-mercaptoethanol,
1 mM benzamidine and 0.1 mM PMSF. Lysates were clarified by
centrifugation at 16,000 g for 10 min at 4°C. Protein concentration
was calculated using Bradford assay (Thermo Scientific).
Immunoblotting and immunoprecipitation were performed using
standard procedures. The signal was developed using ECL Western
Blotting Detection Kit (Amersham) on Amersham Hyperfilm ECL
film (Amersham).
Real-time PCR for SGK1, SGK2 and SGK3
Total RNA was isolated using RNA extraction kit (Qiagen), and
cDNA was prepared using iSsript cDNA synthesis Kit (Bio-Rad)
according to manufacturer’s instructions. PCRs were done in 20 ll
volume, containing 5 ll cDNA, 0.5 lM each primer (Invitrogen) and
SSsoFast Eva Green Supermix (BIO-RAD). All PCRs were run as
follows: 95°C for 5 min, followed by 45 cycles at 95°C for 5 s, 60°C
for 30 s. Each sample was run in triplicate in three independent
experiments. 2(DD) Ct method was used to calculate relative mRNA
expression. Ct values were normalised against 18S rRNA, and rela-
tive expression was calculated using DMSO-treated cDNA sample as
a calibrator. Primers used in this study were as follows: SGK1 sense:
50CTAACGTCTTTCTGTCTC30 and anti-sense: 50CATAGGAGTTAT
TGGCAAT30, SGK2 sense: 50CTTCCATCTCACTAACCA30 and anti-
sense: 50CTTTGTTATTAGGGATAGTCA30, SGK3 sense: 50GAAGTGA
ATGGTTTGTCT30 and anti-sense: 50ATATTCTCTTGCCAGGAA30
and 18S sense: 50AATGGCTCATTAAATCAGTT30 and anti-sense:
50CTAGAATTACCACAGTTATCC30.
SGK3 and Rictor knockdown and cell transfection
SGK3 knockdown was performed by using the MISSION shRNA
(Sigma Aldrich) pLKO.1 vectors. Rictor knockdown shRNA
sequence (insert sequence: ACCGGACTTGTGAAGAATCGTATCTTC
TCGAGAAGATACGATTCTTCACAAGTTTTTTGAATTC) was cloned
in pLKO1-puro vector (DU44740). Lentiviruses were produced in
HEK293T cells, by transfecting 70% confluent 15-cm tissue culture
dish with 10 lg DNA (8 lg shRNA-pLKO1-puro, 4 lg pCMVdelta
R8.2 packaging vector (Adgene) and 2 lg pCMV-VSV-G envelope
vector (Adgene)). DNA was mixed with 40 ll of polyethylenimine
in 300 ll Optimem media (Invitrogen). The media containing
viruses was collected and filtered 48 h after transfection. Breast
cancer cell lines were kept in virus containing media for 24 h. Cells
were allowed to recover in fresh media for 24 h, before the media
was replaced with the selection media containing puromycin (2 lg/
ml). The cells were kept in selection media for 10 days before using
for the experiments, unless stated otherwise.
Immunoprecipitation and assay of SGK3, Akt and S6K1
In vitro kinase activity of SGK3, Akt and S6K1 was assayed as
described previously (Bago et al, 2014). Briefly, SGK3, Akt and
S6K1 were immunoprecipitated from 1 mg ZR-75-1 cell lysate.
Immunoprecipitates were washed in sequence with lysis buffer
containing high salt concentration (500 mM NaCl), lysis buffer and
Buffer A (50 mM Tris pH 7.5, 0.1 mM EGTA). Kinase activity was
assessed by measuring [c-32P]ATP incorporation into Crosstide
substrate peptide [GRPRTSSFAEGKK]. The reactions were carried in
40 ll total volume containing 0.1 mM [c-32P]ATP (400–1,000 cpm/
pmol), 10 mM magnesium acetate and 30 lM Crosstide peptide.
Reactions were terminated by adding 10 ll 0.1 M EDTA and spot-
ting 40 ll of the resulting reaction mix on P81 paper, which were
immediately immersed into 50 mM orthophosphoric acid. Papers
were washed at least five times in 50 mM orthophosphoric acid,
rinsed in acetone and air-dried. Radioactivity was quantified by
Cerenkov counting. One unit of enzyme activity was defined as
amount of enzyme that catalyses incorporation of 1 nmol of [c-32P]
ATP into the substrate over 1 min.
Production of recombinant SGK3
SGK3 [S486E]-GST (DU 52370) and SGK3 [R90A S486E]-GST
(DU52372) in pCMV5D vector were transfected in HEK293 cells
using polyethylenimine. The cells were lysed 48 h post-transfection
in the lysis buffer without phosphatase inhibitors following 1-h
incubation in the presence of PDK1 inhibitor (GSK2334470, 5 lM)
and hVps34 inhibitor (VPS34-IN1, 5 lM). The lysates were clarified
by centrifugation, and GST-tagged proteins were affinity purified
using GST-Sepharose beads. The proteins were eluted with 40 mM
glutathione, pH 8.0, aliquoted and stored at 80°C.
SGK3 kinase assay on phospholipid vesicles
Lipid vesicles were prepared as described in Alessi et al (1997b).
Briefly, the mixture containing 1 mM phosphatidlycholine, 1 mM
phosphatidylserine and either 0.01–0.1 mM phosphatidylinositol or
0.01–0.1 mM phosphatidylinositol 3-phosphate in chloroform was
dried under vacuum and further resuspended in kinase assay buffer
(10 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.1 mM EGTA) by vortex-
ing and sonication. Multilamellar vesicles formed in this process
were passed through 0.2-lm filter using lipid extruder, after which a
suspension of smaller unilamellar vesicles was obtained. Solutions
were stored at 4°C at concentrations 10× higher than those used in
the kinase assay and used within 3 days. The kinase assay was
carried out in two stages; in the first stage, 50 ng of SGK3 [S486E]-
GST or SGK3 [R90A, S486E]-GST was incubated with lipid vesicles,
10 mM Mg-acetate and 0.1 mM ATP. The reaction was started by
adding 50 ng of recombinant GST-PDK1 (32 U/mg) (DU954) to
permit activation of SGK3-GST. After 30 min at 30°C, the reaction
was stopped by adding PDK1 inhibitor (GSK2334470, 1 lM). In the
second stage, the reaction mixture was topped up with 0.1 mM ATP
and reaction started by adding 2 lg of recombinant GST-NDRG1
(DU1557) to permit phosphorylation by activated SGK3-GST. The
assay was carried out for 30 min at 30°C. The reaction was stopped
by adding 4× LDS sample buffer.
Determination cell growth in vitro
For growth assays, BT-474c cells were seeded in 12-well plates at a
density of 1 × 105 cells/well and left to adhere overnight. Cells were
then treated with MK-2206, AZD5363 and 14h inhibitors and imaged
every 4 h on the Incucyte ZOOM (Essen Bioscience) for up to
4 weeks to give a measure of cell confluency. Media was refreshed
every 4–5 days. Inhibitor treatments were carried out as described
in figure legends.
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Animal studies and IHC
Experiments involving mice were in accordance with Institutional
Guidelines of Memorial Sloan Kettering Cancer Center (Protocol
number 12-10-019). Animals were housed in air-filtered laminar
flow cabinets with a 12-h light cycle and food and water ad libi-
tum. BT-474 VH2 (Baselga et al, 1998) were resuspended in 1:1
Complete media/Matrigel (Corning) and injected subcutaneously
into the flanks of 6-week-old female athymic Foxn1nu nude mice
(Harlan Laboratories). Animals’ drinking water was supplemented
with 1 lM 17b-E2 (Sigma). When tumours reached a volume of
~150 mm3, mice were randomised, treated, and tumours were
measured twice a week. Tumour volume was determined using
the following formula: (length × width2)  2. Tumour growth
was represented as the fold change mean  SEM. Treatments
were as follows: MK-2206 (100 mg × kg1 in 30% Captisol
(Sigma), 5 times/week, p.o.) and 14h (25 mg × kg1 in 40% of
3:1 Glycofurol/Kolliphor RH 40 mixture (Sigma) in 0.9% saline,
5 times/week, p.o.). Tumours were harvested at the end of the
experiment 4 h after the last dosage, fixed in 4% formaldehyde
in PBS and paraffin-embedded. IHC was performed on a Ventana
Discovery XT processor platform using standard protocols and the
following antibodies from Cell Signalling Technology: pAkt(S473)
(#4060), 1:70; pPRAS40(T246) (#2997), 1:50; pS6 (S240/4)
(#5364), 1:500; pNDRG1 (T346) (#5482), 1:200; Cleaved Caspase-
3 (#9664), 1:50. Primary staining was followed by 60 min incuba-
tion with biotinylated goat anti-rabbit IgG (Vector labs) 1:200.
Blocker D, Streptavidin-HRP and DAB detection kit (Ventana
Medical Systems) were used according to the manufacturer
instructions.
NanoString analysis
ZR-75-1 cells were collected, washed in PBS and snap-frozen.
Cell pellets were resuspended at a concentration of ~6,500 cells/ll
in RLT buffer (Qiagen). The equivalent of ~10,000 cells (~1.5 ll)
was employed for direct kinase mRNA quantification, without
the need for further mRNA purification or amplification. mRNAs
were hybridised to NanoString human kinome barcode probes
and control code sets, and kinase mRNA levels quantified using
the nCounter colour barcoding system after count normalisation
with internal housekeeping genes and 8 negative controls. For
total copy numbers, triplicate normalised count values were
averaged, and to calculate fold induction, means were divided
by triplicate mean values from matched DMSO controls. P-values
were calculated using unpaired t-test (GraphPad Prism software)
by employing treated and control count data for each kinase
mRNA.
Protein kinase profiling
Protein kinase profiling against Dundee panel of 140 protein kinases
was undertaken at the International Centre for Protein Kinase Profil-
ing. The result for each kinase was presented as a mean kinase
activity of the reaction taken in triplicate relative to a control sample
treated with DMSO.
Assay conditions and abbreviations are available at http://
www.kinase-screen.mrc.ac.uk.
Statistical analysis
All experiments presented in this paper were performed at least
twice, and similar results were obtained. Error bars indicate stan-
dard deviation.
Expanded View for this article is available online.
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